Opigolix
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2010 (NCT02368912)
Timeline
Indications
Mechanism of action
- Gonadotropin-releasing hormone receptorANTAGONIST
GNRHR antagonist
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H](O)C(=N)NS(=O)(=O)c1cc(C(=O)C(C(=O)c2cc(F)ccc2F)=C2Nc3ccccc3N2)ccc1F- Mol. weight
- 544.51 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989969 ↗
Also known as
- asp1707
- asp1707
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02884635 | Phase 2 | Sep 1, 2016 | Astellas |
| NCT02867306 | Phase 1 | Jul 1, 2016 | Astellas |
| NCT02175407 | Phase 1 | Apr 1, 2014 | Astellas |
| NCT01767090 | Phase 2 | Dec 1, 2012 | Astellas |
| NCT02106780 | Phase 1 | Aug 1, 2011 | Astellas |
| NCT02146742 | Phase 1 | Jun 1, 2011 | Astellas |
| NCT02368912 | Phase 1 | Jun 1, 2010 | Astellas |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 7 | 7 | 2 | 2010 |
1 organizations
Page 1 / 1